Bayer spinout ought to boost skinny levloan supply

Bayer’s sale of its animal health unit ought to help a leveraged loan market where supply is still running short of last year’s total — and help loan investors compensate for M&A deals that have dropped out of this year’s pipeline.

  • By Owen Sanderson
  • 03 Jun 2019

The German pharmaceuticals and chemicals group announced last year that it would sell its animal healthcare division, which the Financial Times reported on Sunday could fetch up to €8bn, and potentially attract interest from BC Partners, CVC, Cinven and Permira.

That would mean welcome supply — though likely ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.

Bookrunners of European Leveraged Loans

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 Deutsche Bank 7,350.79 41 6.52%
2 Goldman Sachs 7,236.80 38 6.42%
3 BNP Paribas 7,151.10 53 6.34%
4 Credit Agricole CIB 6,744.91 37 5.98%
5 Barclays 6,209.03 28 5.51%

Bookrunners of European HY Bonds

Rank Lead Manager Amount €m No of issues Share %
  • Last updated
  • Today
1 Citi 4,728.01 24 9.17%
2 JPMorgan 3,649.83 29 7.08%
3 Deutsche Bank 3,638.27 22 7.05%
4 Barclays 3,441.80 22 6.67%
5 Goldman Sachs 3,389.62 26 6.57%

Bookrunners of Dollar Denominated HY Bonds

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 Citi 18,847.11 143 9.43%
2 JPMorgan 18,279.02 147 9.15%
3 Goldman Sachs 14,831.56 109 7.42%
4 Bank of America Merrill Lynch 14,255.85 117 7.13%
5 Morgan Stanley 12,912.93 86 6.46%